A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study

被引：0
|
作者：
Wedzicha, Jadwiga A. [1 ]
Decramer, Marc [2 ]
Vestbo, Jorgen [3 ]
Gallagher, Nicola [4 ]
Kim, Han-Joo [5 ]
McBryan, Danny [6 ]
Banerji, Donald [5 ]
机构：
[1] UCL, Dept Acad Resp Med, London, England
[2] Univ Leuven, Univ Hosp, Div Resp, Leuven, Belgium
[3] Manchester Acad Hlth Sci Ctr, Resp Res Grp, Manchester, Lancs, England
[4] Novartis Horsham Res Ctr, Primary Care, Horsham, W Sussex, England
[5] Novartis Pharmaceut, Primary Care, E Hanover, NJ USA
[6] Novartis Pharma AG, Primary Care, Basel, Switzerland
来源：
EUROPEAN RESPIRATORY JOURNAL | 2013年 / 42卷
关键词：
COPD; -; management; Bronchodilators; Exacerbation;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
2208
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Once-Daily Indacaterol/glycopyrronium Reduces The Rate And Risk Of Moderate Or Severe Exacerbations Compared With Twice-Daily Salmeterol/fluticasone In A Subset Of Gold Group D COPD Patients With A History Of ≥2 Exacerbations Or 1 Hospitalization: The Flame Study
    Vogelmeier, C.
    Wedzicha, J.
    Donohue, J.
    Fucile, S.
    Yadao, A.
    Ayers, T.
    Thach, C.
    Taylor, A. Fowler
    Fogel, R.
    Patalano, F.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [32] ADHERENCE WITH ONCE-DAILY FLUTICASONE FUROATE/VILANTEROL COMPARED TO TWICE-DAILY BUDESONIDE/FORMOTEROL OR FLUTICASONE PROPIONATE/SALMETEROL IN ASTHMA
    Averell, C.
    Stanford, R.
    Laliberte, F.
    Wu, J.
    Germain, G.
    Duh, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S39 - S39
  • [33] Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
    Decramer, Marc
    Wedzicha, Jadwiga A.
    Ficker, Joachim H.
    FowlerTaylor, Angel
    D'Andrea, Peter
    Arrasate, Christie
    Chen, Hungta
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [34] Once-Daily QVA149 Reduces Exacerbations and Improves Health Status in Comparison With Glycopyrronium and Tiotropium in Patients With Severe-to-Very Severe COPD: The SPARK Study
    Wedzicha, Jadwiga
    Ficker, Joachim
    FowlerTaylor, Angel
    D'Andrea, Peter
    Arrasate, Christie
    Chen, Hungta
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [35] Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study (vol 1, pg 51, 2013)
    Vogelmeier, C. F.
    Bateman, E. D.
    Pallante, J.
    LANCET RESPIRATORY MEDICINE, 2013, 1 (02): : 101 - 101
  • [36] LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD
    Zhong, Nanshan
    Wang, Changzheng
    Zhou, Xiangdong
    Zhang, Nuofu
    Humphries, Michael
    Wang, Linda
    Thach, Chau
    Patalano, Francesco
    Banerji, Donald
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 : 1015 - 1026
  • [37] Patients With Severe COPD Show Significant Improvements in Dyspnea and Lung Function With Once-Daily QVA149: The Blaze Study
    D'Urzo, Anthony
    Mahler, Donald
    Worth, Heinrich
    White, Tracy
    Alagappan, Vijay
    Chen, Hungta
    Kulich, Karoly
    Gallagher, Nicola
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [38] Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study
    Mahler, Donald A.
    Decramer, Marc
    D'Urzo, Anthony
    Worth, Heinrich
    White, Tracy
    Alagappan, Vijay
    Chen, Hungta
    Kulich, Karoly
    Gallagher, Nicola
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [39] Once-Daily Qva149 Improves Dyspnea, Quality Of Life And Reduces The Rate Of Exacerbations Compared To Tiotropium Plus Formoterol In COPD Patients: The Quantify Study
    Korn, S.
    Gebner, C.
    Schurmann, W.
    Forster, K.
    Sieder, C.
    Hiltl, S.
    Buhl, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [40] Once-Daily Qva149 Provides Clinically Meaningful Improvements In Lung Function And Clinical Outcomes Versus Placebo, Indacaterol, Glycopyrronium, Tiotropium And Salmeterol/fluticasone In Patients With COPD
    Vogelmeier, C.
    Dahl, R.
    D'Urzo, T.
    Chen, H.
    Green, Y.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
12345